Tata Memorial Hospital conducts pilot study for triple negative breast cancer
Advertisement
Mumbai : Tata Memorial Hospital has initiated a pilot study to provide cheaper drugs for patients suffering from triple negative breast cancer.
The hospital is currently studying the effects of a combination of anti-diabetic and chemotherapy drugs, costing less than Rs 120 a month.
The initial observations made under the study indicate an improved survival rate of 40% in a section of breast cancer patients. Triple negative breast cancer is mostly found in young women, and is difficult to treat. At the Tata Memorial Hospital there are 33% of such cases.
The initial study conducted at the hospital involved 64 patients at Chiplun-based outreach hospital attached to Tata, who were treated using the drug combination. The results found that five-year survival rate of 37 women who took the doses rose to 90%, who took two pills of anti-cancer and one anti-diabetic drug every day for one-and-a-half years. Patients who didn’t take the drugs have a 50% chance of survival in comparison to the patients in the study.
The hospital is currently studying the effects of a combination of anti-diabetic and chemotherapy drugs, costing less than Rs 120 a month.
The initial observations made under the study indicate an improved survival rate of 40% in a section of breast cancer patients. Triple negative breast cancer is mostly found in young women, and is difficult to treat. At the Tata Memorial Hospital there are 33% of such cases.
The initial study conducted at the hospital involved 64 patients at Chiplun-based outreach hospital attached to Tata, who were treated using the drug combination. The results found that five-year survival rate of 37 women who took the doses rose to 90%, who took two pills of anti-cancer and one anti-diabetic drug every day for one-and-a-half years. Patients who didn’t take the drugs have a 50% chance of survival in comparison to the patients in the study.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.